Literature DB >> 18715571

Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis.

Edgar Meinl1, Markus Krumbholz, Tobias Derfuss, Andreas Junker, Reinhard Hohlfeld.   

Abstract

In multiple sclerosis (MS) the CNS is not only the target of the pathological immune response, but the CNS itself becomes an immunological compartment during the course of the disease. This comprises (i) inflammation beyond classical white matter lesions, (ii) intrathecal Ig production with oligoclonal bands, (iii) an environment fostering immune cell persistence, (iv) follicle-like aggregates in the meninges, (v) a disruption of the blood-brain barrier also outside of active lesions, which allows influx of autoantibodies possibly promoting demyelination or axonal injury and influx of fibrinogen driving inflammation.

Entities:  

Mesh:

Year:  2008        PMID: 18715571     DOI: 10.1016/j.jns.2008.06.032

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  23 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 2.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

4.  Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis.

Authors:  Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

Review 5.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

Review 6.  Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations.

Authors:  Norbert Müller
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

7.  Continuous Immune-Modulatory Effects of Human Olig2+ Precursor Cells Attenuating a Chronic-Active Model of Multiple Sclerosis.

Authors:  Yossi Nishri; David Hampton; Etti Ben-Shushan; Nina Fainstein; Dario Magnani; Michal Aharonowiz; Benjamin E Reubinoff; Siddharthan Chandran; Tamir Ben-Hur
Journal:  Mol Neurobiol       Date:  2019-10-28       Impact factor: 5.590

Review 8.  Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.

Authors:  Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel
Journal:  Curr Treat Options Neurol       Date:  2019-10-17       Impact factor: 3.598

Review 9.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

10.  Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Authors:  Mohsen Khademi; Ann M Dring; Jonathan D Gilthorpe; Anna Wuolikainen; Faiez Al Nimer; Robert A Harris; Magnus Andersson; Lou Brundin; Fredrik Piehl; Tomas Olsson; Anders Svenningsson
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.